Joao A De Andrade

List of Publications by Year
in descending order

50	3,146	279487	243296
papers	citations	23 h-index	44 g-index

54	54	54	3369
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respiratory Research, 2022, 23, 3.	1.4	1
2	Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. Lung, 2022, 200, 11-18.	1.4	2
3	Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease. Chest, 2022, 162, 145-155.	0.4	24
4	Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis. Journal of Medical Economics, 2022, 25, 532-540.	1.0	2
5	Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2021, 15, 117954842110060.	0.5	7
6	Citrullinated vimentin mediates development and progression of lung fibrosis. Science Translational Medicine, 2021, 13, .	5.8	60
7	Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry. Respiratory Medicine, 2021, 189, 106637.	1.3	4
8	The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis. Respiratory Medicine, 2020, 161, 105821.	1.3	12
9	Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulmonary Medicine, 2020, 20, 191.	0.8	6
10	Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. BMJ Open Respiratory Research, 2020, 7, e000567.	1.2	15
11	Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest, 2020, 157, 1522-1530.	0.4	14
12	Predicting Outcome in Idiopathic Pulmonary Fibrosis: Addition of Fibrotic Score at Thin-Section CT of the Chest to Gender, Age, and Physiology Score Improves the Prediction Model. Radiology: Cardiothoracic Imaging, 2019, 1, e180029.	0.9	10
13	Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS ONE, 2019, 14, e0221905.	1.1	31
14	Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respiratory Research, 2019, 20, 105.	1.4	44
15	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	2.5	90
16	Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L141-L154.	1.3	37
17	Patient Registries in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 160-167.	2.5	41
18	Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European Respiratory Review, 2018, 27, 180074.	3.0	73

#	Article	IF	Citations
19	CHARACTERISTICS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) IN THE US: DATA FROM THE IPF-PRO REGISTRY. Chest, 2018, 154, 397A-398A.	0.4	9
20	The Diagnostic Approach to Interstitial Lung Disease. Current Pulmonology Reports, 2018, 7, 149-159.	0.5	0
21	Baseline characteristics of 1461 participants in the Pulmonary Fibrosis Foundation Patient Registry. , 2018, , .		1
22	Predictors of death or transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry. , 2018, , .		0
23	What Is in a Pattern? That Which We Call Idiopathic Pulmonary Fibrosis by Any Other Pattern Would Behave Alike!. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 10-12.	2.5	3
24	More than meets the eye: IgG4-related disease presenting as isolated interstitial lung disease. Rheumatology, 2017, 56, 1630-1631.	0.9	3
25	Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis. Journal of Immunology, 2017, 199, 1596-1605.	0.4	76
26	Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170057.	3.0	162
27	3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI Insight, 2017, 2, e91377.	2.3	42
28	Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US. , 2017, , .		1
29	Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). , 2017, , .		0
30	Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials. , 2017, , .		1
31	Alveolar epithelial disintegrity in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L185-L191.	1.3	52
32	A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respiratory Medicine, 2016, 115, 33-38.	1.3	11
33	Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 861-868.	2.5	30
34	FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1481-1491.	3.1	147
35	Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Journal of Translational Medicine, 2015, 13, 249.	1.8	105
36	The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). Chest, 2015, 148, 1034-1042.	0.4	37

#	Article	IF	Citations
37	Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2093-2101.	13.9	422
38	Development and Maintenance of a Biospecimen Repository for Clinical Samples Derived from Pulmonary Patients. Clinical and Translational Science, 2014, 7, 336-341.	1.5	2
39	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	2.0	437
40	A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 88-95.	2.5	423
41	Idiopathic Pulmonary Fibrosis. Immunology and Allergy Clinics of North America, 2012, 32, 473-485.	0.7	15
42	New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis. Drugs, 2011, 71, 981-1001.	4.9	56
43	Testing a Simplified High Resolution CT scan Of The Chest (HRCT) Classification As Predictor Of Outcomes In Patients With Interstitial Lung Disease. , 2010, , .		0
44	Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation. Chest, 2009, 136, 237-244.	0.4	34
45	Innovative approaches to the therapy of fibrosis. Current Opinion in Rheumatology, 2009, 21, 649-655.	2.0	21
46	BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 75-81.	2.5	487
47	Association of Protein C and Type 1 Plasminogen Activator Inhibitor with Primary Graft Dysfunction. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 69-74.	2.5	66
48	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ILOPROST INHALATION IN ADULTS WITH ABNORMAL PULMONARY ARTERIAL PRESSURE AND EXERCISE LIMITATION ASSOCIATED WITH IDIOPATHIC PULMONARY FIBROSIS. Chest, 2007, 132, 633A.	0.4	25
49	Thoughts on the Diagnosis and Management of Interstitial Lung Diseases. Southern Medical Journal, 2007, 100, 555-556.	0.3	1
50	Association of Reactive Nitrogen Species Metabolites, Myeloperoxidase, and Airway Inflammation in Lung Transplants. Journal of Investigative Medicine, 2001, 49, 166-172.	0.7	3